Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 LUNA Trial Of ADVM-022 In Wet AMD
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial
-
Short Volatility Alert: Adverum Biotechnologies, Inc.
On Tuesday, shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) experienced volatile short activity. After the activity, the stock price went down -2.74% to $0.9259.
The overall sentiment for ADVM has been Bearish.
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression And Improvement In Anatomic Outcomes After A Single IVT Injection Of ADVM-022 In The OPTIC Study In Wet AMD
- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD)
- New data highlight
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
Adverum Biotechnologies Inc (NASDAQ:ADVM) announced the presentation of a new post-hoc analysis from the OPTIC study of ADVM-022 in wet age-related…
